טוען...
North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
BACKGROUND: According to the World Health Organization, glaucoma is a leading cause of irreversible blindness worldwide. By 2020, 80 million people will be affected by glaucoma in the world, which represents a significant financial burden to society. Glaucoma medications alone make up 38–52% of the...
שמור ב:
| הוצא לאור ב: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6924989/ https://ncbi.nlm.nih.gov/pubmed/31908505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S156558 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|